Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data



    OTTAWA, April 11 /CNW/ - Liponex Inc. (TSX:LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," today announced
information from further analysis of the Phase I/II Clinical Trial of its lead
product, CRD5. CRD5 is being developed for the treatment of dyslipidemia and
heart disease.
    A detailed review of patient information indicated that all blood
chemistry and blood pressure measurements were within the normal or expected
ranges. CRD5 was shown to be safe in dyslipidemic patients. In addition, the
drug was well-tolerated in the patient group, with the exception of the
reported GI adverse events that led to the cessation of the 5 gram dosing
phase.
    As previously reported, the overall mean HDL increase was 5% at both the
1g (n=50) and 3g (n=40) dosing levels but the patient to patient variation was
high. While some patients had a negative response, over 20% of patients
achieved more than a 10% rise in HDL at the lower dose levels.
    The patient information was reviewed to determine if there were any
patient characteristics that had an impact on the efficacy of CRD5. Some
patients were taking other medications during the trial that may have had
lipid altering effects and these subjects appeared to have reduced response to
CRD5. Data from these subjects were removed and the trial results were
reanalyzed. CRD5 appeared to be more effective in patients with baseline
plasma HDL-cholesterol levels of less than 0.9 mM. This level of HDL is
considered to be abnormal and is associated with elevated risk of developing
heart disease. Those patients (n=17) with starting HDL levels below 0.9 mM
averaged an 11% increase in HDL levels from baseline at the 3 gram CRD5 dosing
level.
    Of note, several patients were identified to have taken proton pump
inhibitors (PPI), such as ranitidine and lansoprazole, which inhibit the
secretion of gastric acid and reduce the acidity of the stomach. Patients that
took PPI regularly during the trial showed an increased CRD5 efficacy with a
mean HDL increase from baseline of 16% at 1 gram (n=4) and 14% at 3 grams
(n=3).
    "We are very encouraged by these results. We are seeing the best effect
in patients that can most benefit from CRD5, at dose levels that are
commercially viable," said Bill Dickie, President and CEO of Liponex. "These
results, particularly the impact of PPI on CRD5 efficacy, support our ongoing
preclinical studies and guide our strategy to optimize the formulation and
dosing regimen for CRD5 clinical development."
    The company believes that it can resolve CRD5 pH sensitivity and boost
the efficacy of CRD5 with well-established enteric coating strategies.
Preclinical experimental work is underway to confirm this view and then an
additional clinical trial will be undertaken with results expected in the
first quarter of 2008. The company has filed a novel formulation patent
application to cover these initial findings and to further protect its
competitive position.

    About Liponex

    Liponex is a biopharmaceutical company specializing in developing
products related to High Density Lipoprotein (HDL), often called "good
cholesterol." Its drug candidates relate to the various roles of HDL as a
transport vehicle, including removing excess cholesterol from the body,
delivering molecules to cells and removing unwanted materials from the body.
Liponex is listed on the TSX under the ticker "LPX". For more information on
Liponex, visit www.liponex.ca.

    Certain of the statements contained in this press release contain
forward-looking statements which involve known and unknown risks,
uncertainties and other important factors which may cause the actual results,
performance or achievements of the Company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Statements of
"belief" with respect to reformulation, the undertaking of an additional
clinical trial for CRD5 as well as CRD5's efficacy in raising HDL levels, are
based primarily upon results derived to date from the Company's pre-clinical
research and development and its results from completed Phase I and Phase I/II
clinical trials. While the Company believes that it has reasonable scientific
basis upon which to make such statements, it is not possible to predict
whether a new therapeutic agent will be prove to be safe and/or effective in
humans. The Company cannot guarantee that it actually will achieve the plans,
intentions or expectations. and undue reliance should not be placed on those
forward-looking statements. The Company does not expect to update
forward-looking statements continually as conditions change. Investors are
referred to the full discussion of risk factors associated with the Company's
business contained in the Company's periodic regulatory filings, which can be
found in the SEDAR database at www.sedar.com.

    %SEDAR: 00022196E




For further information:

For further information: Investor Relations, Joanna Longo, The Equicom
Group Inc., (416) 815-0700 ext. 233, jlongo@equicomgroup.com; Media Relations,
Linda Forrest, inmedia Public Relations, (613) 234-7227 ext. 234,
lforrest@inmedia.com

Organization Profile

LIPONEX INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890